Conclusions
Compared to more conventional medicinal products, the non-clinical development program for cell-based products was more tailored and focussing on proof-of-concept. For tumourigenicity an in vitroapproach may suffice. Total omission of in vivo studies appears to be possible for products with sufficient clinical experience.